Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July- -Second Subject Dosed …